Skip to content
DataLookout
Menu

PROTECTNCT07647029

A Clinical Study on Prophylactic RespOnse To hEtrombopag for Secondary Prevention in Anti-Cancer Therapy-induced Thrombocytopeniae

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 6 more changesShow less
    • Eligibility criteria expanded, about 27 words
    • Primary endpoints: details revised at 1 of 1 entry
    • Study sites: 0 to 1
    • Start date changed from estimate of May 28, 2026 to Jul 16, 2026
    • Secondary endpoints: details revised at 2 of 6 entries
    • Publications: details revised at 7 of 7 entries
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Incidence of grade ≥2 thrombocytopenia (PLT < 75×10⁹/L)
Timeframe: At the end of Cycle 2 (each cycle ≥21 days)

Secondary (6)

Duration of grade ≥2 thrombocytopenia (PLT < 75×10⁹/L)
Incidence and duration of grade ≥3 thrombocytopenia (PLT < 50×10⁹/L)
Proportion of patients who successfully completed two chemotherapy cycles without thrombocytopenia-related modifications to subsequent antineoplastic therapy
Proportion of patients without rescue therapy for thrombocytopenia (e.g., platelet transfusion, interleukin-11, recombinant human thrombopoietin)
Nadir and peak platelet counts
Show 1 moreShow less
Incidence of adverse events

Arms and interventions

No prophylactic use of hetrombopagNo intervention

No prophylactic use of hetrombopag

Continuous Hetrombopag for 2 CyclesExperimental

Hetrombopag at an initial dose of 7.5 mg once daily, administered from Day 1 of the first chemotherapy cycle (C1D1) continuously until the end of the second chemotherapy cycle

Cyclic 14-day Hetrombopag for 2 CyclesExperimental

Hetrombopag at an initial dose of 7.5 mg once daily, administered from Day 1 (C1D1) to Day 14 (C1D14) of the first chemotherapy cycle; the dosage and administration schedule in the second chemotherapy cycle were identical to those in the first cycle

Drugs: Continuous Hetrombopag for 2 Cycles, Cyclic 14-day Hetrombopag for 2 Cycles

Sites

1 site in 1 country

  • Fudan University Shanghai Cancer centerShanghai, Shanghai Municipality, China